Cevik, M., Thompson, L. C., Upton, C., Rolla, V. C., Malahleha, M., Mmbaga, B., . . . Gillespie, S. H. (2024). Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: A phase 2c, open-label, multicentre, partially randomised controlled trial.
Referência de acordo com a norma ChicagoCevik, Muge, et al. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for Drug-sensitive and Drug-resistant Pulmonary Tuberculosis Treatment: A Phase 2c, Open-label, Multicentre, Partially Randomised Controlled Trial. 2024.
Referência de acordo com a norma MLACevik, Muge, et al. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for Drug-sensitive and Drug-resistant Pulmonary Tuberculosis Treatment: A Phase 2c, Open-label, Multicentre, Partially Randomised Controlled Trial. 2024.